JP A23014A00 JP 2022-167362 2022-10-19 Astellas Pharma Inc. がん治療におけるＰＤ－１シグナル阻害剤との組み合わせによる抗ＣＬＤＮ４－抗ＣＤ１３７二重特異性抗体の使用 USE OF ANTI-CLDN4/ANTI-CD137 BISPECIFIC ANTIBODY COMBINED WITH PD-1 SIGNAL INHIBITOR FOR CANCER TREATMENT 14 2136 DNA PAT misc_feature 1..2136 note hKM3900_tA2-32LH HC source 1..2136 mol_type other DNA organism synthetic construct gaagtgcagctggttcagtctggcgccgaagtgaagaaacctggcgcctccgtgaagatctcctgcaaggcttctggctacaccttcaccgactactacatgaactgggtccgacaggctcctggacagggacttgagtggatgggagatgtggtgcccaacaacggcgtgcccacctacaaccagaaattcaagggcagagtgaccatcaccgccgacaagtctacctccaccgcctacatggaactgcggagcctgagatctgaggacaccgccgtgtactactgcgccagacctcactactactacgccggcagatctggcgccatggattattggggacagggcaccctggtcaccgtgtcctctgctagcacaaagggcccctctgtgttccctctggctcctagctctaagtccacctctggcggaacagctgctctgggctgtctggtcaaggactacttccctgagcctgtgaccgtgtcttggaactctggcgctctgacatccggcgtgcacacatttccagctgtgctgcagtcctccggcctgtactctctgtcctctgtcgtgaccgtgccttccagctctctgggaacccagacctacatctgcaatgtgaaccacaagccttccaacaccaaggtggacaagaaggtggaacccaagtcctgcgacaagacccacacctgtcctccatgtcctgctccagaagctgctggcggaccttccgtgttcctgtttcctccaaagcctaaggacaccctgatgatctctcggacccctgaagtgacctgcgtggtggtggatgtgtctcacgaggacccagaagtgaagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaagcctagagaggaacagtacaactccacctacagagtggtgtccgtgctgaccgtgctgcaccaggattggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctgccggcatcgaaaagaccatctccaaggccaagggccagcctagggaaccccaggtttacaccttgccaccttctcgggacgagctgaccaagaaccaggtgtccctgacctgtctcgtgaagggcttctacccctccgatatcgccgtggaatgggagtctaatggccagcctgagaacaactacaagacaacccctcctgtgctggactccgacggctcattcttcctgtactccaagctgacagtggacaagtccagatggcagcagggcaacgtgttctcctgcagcgtgatgcacgaggccctgcacaatcactacacacagaagtctctgtctctgagccccggcaaaggtggcggaggatctggcggaggcggatcccaatctgttctgacccaacctccttccgcctctggcacacctggccagagagtgaccatctcttgctccggctcctcctccaacatcggctctaacaccgtgaactggtatcagcagttccccggcaccgctcctaagctgctgatctactccaacaaccagcggccttccggcgtgcccgatagattctctggctctaagtccggcacctctgccagcctggctatttctggactgcagagcgaggacgaggccgactattattgtgccggctgggacgactctctgaacggccctgtttttggcggtggcaccaaactgacagtgcttggaggcggtggtggatcaggcggcggtggaagtggtggtggtggtagcggaggtggtggatctcaggtgcagctccaagagtctggacctggcctcgtgaagccttccgagacactgtctctgacctgcacagtgtccggcggctctatctctggctactactggtcctggatcagacagcctcctggcaagggactcgagtggatcggctacatctactactctggcttcaccaactacaaccccagcctgaagtcccgcgtgaccatcagcgtggacacctctaagaaccagttctctctgaagctgtcctccgtgaccgccgctgataccgctgtgtattactgcacccgggaccacagccactactactacatggacgtgtggggacagggaacaaccgtgacagtgtcctcc 712 AA PAT REGION 1..712 note Synthetic Construct source 1..712 mol_type protein organism synthetic construct EVQLVQSGAEVKKPGASVKISCKASGYTFTDYYMNWVRQAPGQGLEWMGDVVPNNGVPTYNQKFKGRVTITADKSTSTAYMELRSLRSEDTAVYYCARPHYYYAGRSGAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAGIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSQSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQFPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAGWDDSLNGPVFGGGTKLTVLGGGGGSGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGGSISGYYWSWIRQPPGKGLEWIGYIYYSGFTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCTRDHSHYYYMDVWGQGTTVTVSS 645 DNA PAT misc_feature 1..645 note hKM3900 LC source 1..645 mol_type other DNA organism synthetic construct gacatccagctgacccagtctccatcctctctgtctgcctctgtgggcgacagagtgacaattacctgcaccgcctcctccaccgtgtcctctacctacctgcactggtatcagcagaagcccggcaaggctcccaagctgctgatctactccacctccaatctggcctctggcgtgccctctagattctccggatctggctctggaaccgactataccctgacaatctccagcctgcagcctgaggacttcgccacctactactgccaccagtaccacagatccccacctacctttggccagggcaccaagctggaaatcaagcgtacggtggccgctccttccgtgttcatcttcccaccttccgacgagcagctgaagtccggcacagcttctgtcgtgtgcctgctgaacaacttctaccctcgggaagccaaggtgcagtggaaggtggacaatgccctgcagtccggcaactcccaagagtctgtgaccgagcaggactccaaggacagcacctacagcctgtcctccacactgaccctgtccaaggccgactacgagaagcacaaggtgtacgcctgcgaagtgacccatcagggcctgtctagccctgtgaccaagtctttcaaccggggcgagtgc 215 AA PAT REGION 1..215 note Synthetic Construct source 1..215 mol_type protein organism synthetic construct DIQLTQSPSSLSASVGDRVTITCTASSTVSSTYLHWYQQKPGKAPKLLIYSTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCHQYHRSPPTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 4 AA PAT REGION 1..4 note GS linker PEPTIDE 1..4 source 1..4 mol_type protein organism synthetic construct GGGS 4 AA PAT REGION 1..4 note GS linker PEPTIDE 1..4 source 1..4 mol_type protein organism synthetic construct SGGG 5 AA PAT REGION 1..5 note GS linker PEPTIDE 1..5 source 1..5 mol_type protein organism synthetic construct GGGGS 5 AA PAT REGION 1..5 note GS linker PEPTIDE 1..5 source 1..5 mol_type protein organism synthetic construct SGGGG 6 AA PAT REGION 1..6 note GS linker PEPTIDE 1..6 source 1..6 mol_type protein organism synthetic construct GGGGGS 6 AA PAT REGION 1..6 note GS linker PEPTIDE 1..6 source 1..6 mol_type protein organism synthetic construct SGGGGG 7 AA PAT REGION 1..7 note GS linker PEPTIDE 1..7 source 1..7 mol_type protein organism synthetic construct GGGGGGS 7 AA PAT REGION 1..7 note GS linker PEPTIDE 1..7 source 1..7 mol_type protein organism synthetic construct SGGGGGG 10 AA PAT REGION 1..10 note GS linker PEPTIDE 1..10 source 1..10 mol_type protein organism synthetic construct GGGGSGGGGS 5 AA PAT REGION 1..5 note GKPGS linker PEPTIDE 1..5 source 1..5 mol_type protein organism synthetic construct GKPGS